Title: Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Abstract: Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.
Publication Year: 2008
Publication Date: 2008-04-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 38
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot